Quest Diagnostics, US74834L1008

Quest Diagnostics stock falls 4.29 percent ahead of the open

Published on 09/23/2026 at 05:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 22, 2026, Quest Diagnostics stock stood at USD 234.38 after falling 4.29 percent as proposed Medicare rate cuts pressured laboratory shares.

Automatisierter Laboranalysator mit Blutproben-Röhrchen in klinischem Diagnostiklabor
Quest Diagnostics US74834L1008 zeigt automatisierten Laboranalysator mit Blutproben in modernem Diagnostiklabor fotorealistisch dargestellt, Illustration mit AI erstellt.

Quest Diagnostics stock closed at USD 234.38 on the NYSE on September 22, 2026, down 4.29 percent. The shares underperformed the Nasdaq Composite, which closed at 27,244.28, up 0.45 percent that session.

September 22, 2026 in numbers

Quest Diagnostics Incorporated (ISIN US74834L1008, NYSE: DGX) traded as high as USD 248.84 during the session, while a market report placed volume at 893,281 shares. The close was USD 14.46, or 5.81 percent, below the reported 52-week high of USD 248.84.

As Investing.com reported on September 22, 2026, the Centers for Medicare and Medicaid Services announced proposed laboratory reimbursement reductions of up to 15 percent starting in 2027.

Scheduled event on October 22, 2026

Quest Diagnostics is scheduled to release its third-quarter 2026 financial results before the market opens on October 22, 2026, according to PR Newswire.

Disclaimer...

en | US74834L1008 | QUEST DIAGNOSTICS | boerse | 70161966 | bgmi